Recursion Pharmaceuticals Inc
NASDAQ:RXRX
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
5.7
15.52
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals Inc
Other Equity
Recursion Pharmaceuticals Inc
Other Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Recursion Pharmaceuticals Inc
NASDAQ:RXRX
|
Other Equity
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other Equity
-$2.3B
|
CAGR 3-Years
10%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-10%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Equity
$18.4B
|
CAGR 3-Years
526%
|
CAGR 5-Years
175%
|
CAGR 10-Years
61%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Equity
-$336m
|
CAGR 3-Years
25%
|
CAGR 5-Years
6%
|
CAGR 10-Years
-12%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Equity
-$22.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Equity
$60.2m
|
CAGR 3-Years
82%
|
CAGR 5-Years
29%
|
CAGR 10-Years
8%
|
|
Recursion Pharmaceuticals Inc
Glance View
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. The company is headquartered in Salt Lake City, Utah. The company went IPO on 2021-04-16. The Company’s platform includes the Recursion Operating System, which combines an advanced infrastructure layer to generate proprietary biological and chemical datasets, and the Recursion Map, a suite of custom software, algorithms, and machine learning tools. The Company’s programs include REC-994, REC-2282, REC-4881, and REC-3599. REC-994 is an orally bioavailable, superoxide, scavenger small molecule being developed for the treatment of CCM. REC-2282 is developed for the treatment of neurofibromatosis type 2. REC-4881 is developed for the treatment of familial adenomatous polyposis. REC-3599 is developed for the treatment of GM2 gangliosidosis.
You don't have any saved screeners yet
